Altana forms joint venture with Bracco:
This article was originally published in Clinica
Executive Summary
Altana's diagnostics subsidiary, Byk Gulden (Germany), has formed a joint venture with Bracco (Italy). Ownership will be 51:49 in favour of Bracco. The joint venture will expand the companies' existing co-operation from Germany and Italy to include France, Benelux, Poland, the Czech Republic and Slovakia. Bracco will develop the contrast agents while Byk Gulden will handle production and marketing and gain access to Bracco's MRI and ultrasound contrast agents products. Altana expects its diagnostics turnover to increase from DM 275 million ($194 million) this year to DM 400 million by the year 2000.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.